The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Amgen announces encouraging results in a Phase 3 trial for a new treatment of thyroid eye disease. Viridian Therapeutics is ...

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

Stifel analyst Alex Thompson notes that Amgen (AMGN) announced positive topline results for the Phase 3 on-body infusion study of Tepezza achieving a 77% rate of proptosis response, which comes in ...

Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants ...

Amgen has announced positive topline findings from a phase 3 study evaluating a subcutaneous formulation of Tepezza in adults with moderate to severe active thyroid eye disease (T ...

The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts expressed doubt about its competitive standing.

The biotechnology company said Monday that its under-the-skin version of Tepezza met its primary endpoints in treating moderate-to-severe thyroid eye disease, showing a 77% proptosis response rate, ...

The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall ...

Viridian Therapeutics shares fell after rival Amgen posted positive results for its eye-disease treatment, Tepezza. The stock fell 21% to $14.73, extending some declines seen since reporting its own ...

Amgen’s rare disease drug Tavneos is under mounting regulatory scrutiny, with the FDA warning of serious liver injuries, ...